Sanofi: agreement to acquire Kymab

(CercleFinance.com) - Sanofi announces an agreement to acquire Kymab, a biopharmaceutical company specialising in the clinical development of human monoclonal antibodies, which has indications in immunology and immuno-oncology.


The French healthcare giant will make an upfront payment of approximately 1.1 billion dollars, along with milestone payments of up to 350 million dollars, depending on the completion of various development phases.

Sanofi plans to finance this transaction with available cash. The deal is expected to be completed in the first quarter of 2021, subject to various conditions and particularly the expiry of the US antitrust waiting period.


Copyright (c) 2021 CercleFinance.com. All rights reserved.